drugset
drugset / Trial / NCT07086755

Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury

NCT07086755 ↗

Phase 2/3 Recruiting 1100 enrolled Bentley J. Bobrow Akebia Therapeutics · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to assess the efficacy and safety of vadadustat for treating hospitalized patients with nonintubated Acute Respiratory Distress Syndrome (ARDS) secondary to pathogen-associated lung injury.

Timeline

Start
2025-10-23
Primary completion
2026-07-01
Completion
2026-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vadadustat Small molecule 900 mg Oral
Subject Vadadustat Small molecule 1200 mg Oral

Indications

acute lung injury acute respiratory distress syndrome